Navigation Links
Protecting specific area of the brain during radiation therapy substantially reduces memory loss
Date:9/23/2013

ATLANTA Sept. 23, 2013. Protecting the stem cells that reside in and around the hippocampus a C-shaped area in the temporal lobe on both sides of the brain associated with the ability to form and store memories substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the Phase II clinical trial of patients with brain metastases are being presented today at the American Society for Radiation Oncology (ASTRO) annual meeting.

"Memory loss, especially short-term recall, is an important consideration for patients receiving whole-brain radiotherapy," says the study's co-principal investigator, Minesh P. Mehta, M.B., Ch.B., professor of radiation oncology at the University of Maryland School of Medicine. "We found that reducing the radiation dose to the stem-cell niches surrounding the hippocampus during treatment was clearly associated with memory preservation without an inordinate risk of relapse in that portion of the brain. The findings far exceeded our expectations."

Based on previous research, the predicted rate of cognitive decline at four months for patients receiving whole-brain radiation for brain metastases was 30 percent. Researchers designed the clinical trial so that a positive result would be a rate reduced by half, to 15 percent. The observed rate in the trial was actually 7 percent significantly better than the baseline rate of 30 percent. With a third fewer patients to evaluate, the rate of decline observed at six months was 2 percent, although comparable data from the historic control study were not available.

"These Phase II results, while not absolutely conclusive, offer very important insights which we hope to validate in a larger, randomized Phase III clinical trial," says Dr. Mehta, a radiation oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center who chairs the Radiation Therapy Oncology Group (RTOG) brain tumor committee. The RTOG, which managed the Phase II trial, also plans to manage the Phase III Study.

Co-principal investigator Vinai Gondi, M.D., will present the findings at the plenary session at the ASTRO annual meeting in Atlanta. He practices at Central DuPage Hospital Cancer Center in Warrenville, Ill.

E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine, says, "Preserving neurocognitive function is extremely important in treating patients with brain metastases, and the results of this latest study on hippocampal-avoidance radiotherapy led by Dr. Mehta are very encouraging. This technique, if validated in a randomized clinical trial, will give physicians a significant new tool to help maintain patients' quality of life while aggressively treating their cancer."

Patients in the study, the majority of them with lung cancer that had spread to the brain, were treated with intensity-modulated radiation therapy (IMRT), which enabled doctors to shape the radiation beams to avoid the hippocampus. Researchers used a standardized cognitive function assessment the Hopkins Verbal Learning Test (HVLT) to measure patients' baseline memory, such as their ability to recall information immediately or after a delay, with follow-up at two, four and six months.

A total of 113 patients were recruited between 2011 and 2013; investigators were able to evaluate 42 patients at four months and 29 patients at six months. The median survival for the participants was 6.8 months. Three patients (4.5 percent) experienced progression of their disease in the hippocampal region, which was within the expected range.

Dr. Mehta says that the radiation affects cognitive function by damaging nerve cells as well as stem cells, which help to regenerate nerve cells that support memory formation. "These stem-cell niches are exquisitely sensitive to radiation and are involved in neurogenesis the process of generating new neurons, or nerve cells. Although we call it hippocampal-avoidance radiotherapy, we really are targeting the stem-cell niches in and around the hippocampus," Dr. Mehta says.

He notes that factors other than radiation may also contribute to cognitive decline in patients with brain metastases, including medicines to control seizures or swelling in the brain. The cancer itself may also have an effect.


'/>"/>

Contact: Karen Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert

Related medicine news :

1. Disaster Webinar to Detail Protecting Data and Apps in the Cloud
2. Expert to Offer Tips on Protecting Data from Cyber Attacks
3. Protecting the body in good times and bad
4. TheBeautyPlace.com Features Protecting the Skin This Summer Has Never Been Easier, Just Remember Multiples of 5
5. Ethical quandary about vaccinations sparked by tension between parental rights and protecting public health
6. Kowalli Offers Tips for Protecting Your Baby This Summer
7. Protecting Landscapes from Wildlife Damage
8. Cosmetic Surgery – Protecting Consumers from Unlicensed Practitioners
9. The Truck Accident Victims’ Guide By Block O’Toole & Murphy, LLP: Protecting Yourself After A Collision With A Tractor-Trailer
10. Young Athletes Urged to Use Face-Protecting Gear
11. TraceLink Life Sciences Cloud Named Amazon AWS Grand Prize Winner for Protecting Patients, Enabling Health, Ensuring Track and Trace Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... ... , ... The Woodlands at John Knox Village , Florida’s first Life ... living and healing, celebrated its grand opening, today. The Woodlands at John Knox Village ... Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village as ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology: